OBM_Logo_Orange_White_RGB-4

Close

  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™ (AVIM therapy)
    • FreeHold Retractors
  • Investor Relations
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial & Filings
    • IR Resources
  • Contact Us

Our Innovations

Pipeline

Advancing a multi-asset pipeline of high-impact therapeutic solutions

Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential for value creation using our partnership-enabled business model.

SWIPE TO SCROLL swipe to scroll
Pipeline Chart

Our flagship product candidates, BackBeat CNT (AVIM therapy) and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:

  • Target mature therapeutic device markets with significant unmet needs
  • Provide high impact procedure-based solutions with rapid adoption potential
  • Offer strategic and financial benefits to a commercial partner and Orchestra BioMed

*Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for: 1The balloon dilatation of the stenotic portion (up to 26 mm length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter; 2The balloon dilation of the de novo stenotic portion (up to 26mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter; 3The balloon dilatation of the stenotic portion (up to 18 mm length) of an infrapopliteal artery (P-3 segment or distal, below the knee, with reference vessel diameter (RVD) 2.25 - 4.0 mm), for the purpose of improving lumen diameter.

Virtue® SAB is investigational and not commercially approved.

BackBeat CNT™ (also known as AVIM therapy) is investigational and not commercially approved.

Orchestra BioMed logo
    •  Who We Are
      Our Approach
      Our People
      Careers
    • Our Innovations
      Pipeline
      Therapeutic Areas
      Virtue® SAB
      BackBeat CNT™
      FreeHold Retractors
    • Investor Relations
      Overview
      News & Events
      Stock Information
      Corporate Governance
      Financial & Filings
      IR Resources
    • Contact Us
      Legal

© 2025 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Disclaimer